☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Boehringer Ingelheim
Boehringer Ingelheim and Sosei Heptares Collaborate for the Development of Therapies to Address Schizophrenia Symptoms
March 11, 2024
Boehringer Ingelheim Reports Results from the P-II Study of Survodutide for the Treatment of Metabolic Dysfunction-Associated Stea...
February 27, 2024
Boehringer Ingelheim Partners with Sleip AI to Employ AI-technology to Diagnose Lameness in Equines
February 19, 2024
Boehringer Ingelheim and Veeva Collaborate for Advancing Clinical and Regulatory Operations in Animal Health
February 15, 2024
Insights+: EMA Marketing Authorization of New Drugs in December 2023
January 23, 2024
Boehringer Ingelheim Collaborated with Riboure Pharmaceuticals to Develop RNAi Based Therapies for the Treatment of Liver Diseases
January 4, 2024
Load more...
Back to Home